Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276) by Rockstroh, J et al.
ORAL PRESENTATION Open Access
Once-daily S/GSK1349572 combination therapy in
antiretroviral-naïve adults: rapid and potent 24-
week antiviral responses in SPRING-1 (ING112276)
J Rockstroh
1*, F Felizarta
2, F Maggiolo
3, F Pulido
4, HJ Stellbrink
5, O Tsybakova
6, P Yeni
7, S Almond
8, C Brothers
9,
I Song
9, S Min
9
From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010
Purpose of study
S/GSK1349572, a next-generation HIV-1 integrase inhi-
bitor, has previously demonstrated potent antiviral activ-
ity in Phase 2a with once-daily, unboosted dosing.
SPRING-1 is an ongoing dose-ranging study designed to
select a dose to for Phase 3 evaluation.
Methods
SPRING-1 is a Phase 2b, multicentre, partially-blinded
study in therapy-naïve adults, randomized 1:1:1:1 to
10mg, 25mg or 50mg of S/GSK1349572 or efavirenz
(EFV) 600mg once-daily with either co-formulated TDF/
FTC or ABC/3TC.
Summary of results
205 subjects received study drug: 86% male, 20% non-
white, 26%>100,000c/mL HIV-1 RNA, 67% TDF/FTC.
Plasma HIV-1 RNA declined rapidly across all S/
GSK1349572 doses with no differences in NRTI sub-
groups. Three protocol-defined virologic failures
occurred, 1 on EFV (<1log10 decline by Week 4), and 2
on S/GSK1349572 (Week 4 and 24 rebound >400c/mL
with no INI mutation detected). No dose-related clinical
or laboratory toxicities were observed. More drug-
related AEs of moderate-or-higher intensity were
reported on EFV (20%) than S/GSK1349572 (6%) arms;
none occurred in more than 1 S/GSK1349572 subject.
The most frequent category of such events reported by
subjects receiving EFV and S/GSK1349572 were gastro-
intestinal (4% vs. 2%, respectively); other frequent events
on EFV were psychiatric (6%) and rash (4%) disorders.
No SAE was considered related to S/GSK1349572. Six
subjects (2: S/GSK1349572 and 4: EFV) withdrew due to
AEs. Mean change from baseline in LDL cholesterol was
+0.023mmol/L among S/GSK1349572 subjects and
+0.468mmol/L among EFV subjects. S/GSK1349572
demonstrated low pharmacokinetic variability and drug
exposure increased with dose. Table 1
Conclusions
S/GSK1349572 administered once-daily without a PK
booster was well tolerated with potent antiviral activity
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Table 1
Planned Week 24 Interim Analysis Results S/GSK1349572 10 mg
(n=53)
S/GSK1349572 25mg
(n=51)
S/GSK1349572 50mg
(n=51)
EFV control
(n=50)
Mean baseline HIV-1 RNA (log10 c/mL) 4.42 4.38 4.58 4.46
%<50c/mL at 24 wks (by TLOVR) 96% (51/53) 90% (46/51) 92% (47/51) 78% (39/50)
Median baseline (change from baseline at 24 weeks) CD4
+ cells/mm3
289 (+159) 330 (+206) 305 (+167) 308 (+110)†
†p=0.008; Wilcoxon two-sample test vs. S/GSK1349572 arms (median change: +176)
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cell increases on S/GSK1349572 merit further observa-
tion and confirmation.
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